Liquidia (NASDAQ:LQDA) Given New $44.00 Price Target at Wells Fargo & Company

Liquidia (NASDAQ:LQDA) had its price objective hoisted by investment analysts at Wells Fargo & Company from $31.00 to $44.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 28.50% from the stock’s previous close.

A number of other analysts have also weighed in on the company. Wall Street Zen lowered Liquidia from a “buy” rating to a “hold” rating in a research report on Sunday, January 18th. Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a report on Thursday. HC Wainwright increased their price target on Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Friday. Finally, BTIG Research lifted their price objective on Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Liquidia Stock Down 0.8%

Shares of LQDA opened at $34.24 on Friday. The company’s 50-day simple moving average is $37.07 and its 200-day simple moving average is $30.84. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. Liquidia has a 1 year low of $11.26 and a 1 year high of $46.67. The stock has a market capitalization of $2.98 billion, a PE ratio of -23.78, a P/E/G ratio of 0.60 and a beta of 0.52.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The business had revenue of $92.02 million during the quarter. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm’s revenue was up 3072.4% on a year-over-year basis. Analysts forecast that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Rajeev Saggar sold 21,142 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $791,345.06. Following the completion of the transaction, the insider directly owned 176,883 shares of the company’s stock, valued at $6,620,730.69. This represents a 10.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Russell Schundler sold 27,289 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the completion of the transaction, the general counsel owned 579,394 shares in the company, valued at $21,686,717.42. This represents a 4.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 212,534 shares of company stock valued at $7,964,719 over the last 90 days. Insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Liquidia by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after purchasing an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after purchasing an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after buying an additional 16,022 shares during the last quarter. Teacher Retirement System of Texas grew its stake in Liquidia by 25.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 17,185 shares of the company’s stock worth $214,000 after buying an additional 3,478 shares during the last quarter. Finally, Sigma Planning Corp increased its position in Liquidia by 6.0% during the second quarter. Sigma Planning Corp now owns 69,185 shares of the company’s stock worth $862,000 after buying an additional 3,910 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: HC Wainwright raised its price target to $55 and maintained a Buy rating, reflecting aggressive upside and materially higher longer‑term EPS forecasts that support a higher valuation. HC Wainwright PT Raise
• Positive Sentiment: Needham and BTIG also bumped price targets (Needham to $54, BTIG to $50) and keep Buy ratings — consistent multi‑broker upgrades amplify buying interest from growth/healthcare investors. Needham PT Raise
• Positive Sentiment: Company reported strong YUTREPIA® adoption: $148.3M FY2025 product sales, $90.1M in Q4, over 3,600 prescriptions and the second consecutive profitable quarter with $190.7M cash — fundamentals that support higher forward earnings expectations. Company Results & Release
• Neutral Sentiment: Quarterly EPS headlines are mixed: Liquidia reported $0.15 EPS (reported by the company), which beat some low-model estimates but missed a higher consensus ($0.33) cited by other services — this divergence produced intraday volatility as investors reconcile differing expectations. Earnings Coverage
• Negative Sentiment: Shares gapped down in early trading after the earnings release amid headlines calling the quarter “weak” relative to some expectations — that initial sell‑off pressured the stock despite the stronger underlying sales and cash metrics. Gap Down Coverage
• Negative Sentiment: Notable insider and institutional selling has been reported (including a recent ~$5.1M manager sale), which may cap upside and concern short‑term investors about supply pressure. Insider/Manager Sale

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).